| 產(chǎn)品名稱 |
VLN6H2 |
| 商品貨號 |
B161771 |
| Organism |
human (B cell); human (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
2 CELLS CONTAIN HERPESVIRUS
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
a regional draining lymph node of a patient with carcinoma of the vulva. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Lymphocytes were isolated from a regional draining lymph node of a patient with carcinoma of the vulva. B lymphocytes were fused with UC 729-6 cells (see ATCC CRL-8061). |
| Clinical Data |
Lymphocytes were isolated from a regional draining lymph node of a patient with carcinoma of the vulva. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against cancer of the vulva |
| Cellular Products |
immunoglobulin; monoclonal antibody; against cancer of the vulva |
| Comments |
The fusion line, CRL-8061, is reported to be EBNA positive. Lymphocytes were isolated from a regional draining lymph node of a patient with carcinoma of the vulva. B lymphocytes were fused with UC 729-6 cells (see ATCC CRL-8061). The antibody recognizes an epitope on a 78000 dalton antigen on A-431 cells and a 66000 dalton antigen on T293H cells. |
| Complete Growth Medium |
Culture medium: Iscove's modified Dulbecco's medium with 4 mM L-glutamine
adjusted to contain 1.5 g/L sodium bicarbonate, 80%; fetal bovine serum, 20%. |
| Subculturing |
Medium Renewal: Every 2 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 2 X 10 exp5 and 8 X 10 exp5 cells/ml. |
| Isotype |
IgG |
| Name of Depositor |
Regents of the University of California |
| U.S. Patent Number |
|
| References |
Glassy MC, Surh C. Human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells. US Patent 4,761,377 dated Aug 2 1988
|
